{
    "nct_id": "NCT03711058",
    "official_title": "A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
    "inclusion_criteria": "* Age â‰¥18 years.\n* Ability to understand and willingness to sign a written informed consent document.\n* Phase I: Must have received all curative treatment options and at least 2 lines of systemic therapy.\n* Phase II: Must have received at least 2 lines of systemic therapy including a fluoropyrimidine, oxaliplatin, and irinotecan-containing regimen. KRAS/NRAS/BRAF wildtype patients must have received or refused anti-EGR.\n* Must have received all curative treatment options and at least 2 lines of systemic and standard therapy.\n* Must have measurable disease based on RECIST 1.1\n* Must have biopsiable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests within 21 days of initial study drug.\n* Men must use acceptable form of birth control while on study.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti- PD-L2, anti-CTLA4, etc.).\n* Prior therapy with a PI3K inhibitor\n* Chemotherapy, target small molecule therapy, investigational therapy, or surgery within 4 weeks prior to first dose of treatment.\n* Has received prior radiotherapy within 2 weeks prior to the start of treatment.\n* Patient who is receiving or have received any other investigational agents within 4 weeks prior to the first dose of treatment.\n* Has received a live vaccine 30 days prior to the first dose of study drug.\n* Has known additional malignancy that is progressing or requires active treatment..\n* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Has symptomatic ascites or has required a paracentesis in the last 12 weeks.\n* Hypersensitivity reaction to study drug.\n* Patients diagnosed of immunodeficiency or are on any immunosuppressive agents within 7 days prior to first dose of study drug.\n* Has active autoimmune disease that has required systemic treatment in the past 12 months, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Infection with HIV or hepatitis B or C.\n* Cytomegalovirus polymerase chain reaction (CMV PCR) positive.\n* Known history or concurrent interstitial lung disease.\n* Type I diabetes or Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin at screening.\n* Uncontrolled cardiovascular disease.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Use of anti-arrhythmic therapy (beta blockers or digoxin are permitted).\n* Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and throughout treatment.\n* Any arterial or venous thrombotic or embolic events within 3 months of start of study drug.\n* Non-healing wound, ulcer, or fracture.\n* Patients with evidence or history of bleeding condition.\n* Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment.\n* Seizure disorder requiring anti-seizure medication.\n* Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.\n* Are pregnant or breastfeeding.\n* Unwilling or unable to follow the study schedule for any reason.",
    "miscellaneous_criteria": ""
}